BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36039416)

  • 21. SLUG-related partial epithelial-to-mesenchymal transition is a transcriptomic prognosticator of head and neck cancer survival.
    Schinke H; Pan M; Akyol M; Zhou J; Shi E; Kranz G; Libl D; Quadt T; Simon F; Canis M; Baumeister P; Gires O
    Mol Oncol; 2022 Jan; 16(2):347-367. PubMed ID: 34382739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity of Head and Neck Squamous Cell Carcinoma Stem Cells.
    Qian X; Nie X; Wollenberg B; Sudhoff H; Kaufmann AM; Albers AE
    Adv Exp Med Biol; 2019; 1139():23-40. PubMed ID: 31134493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.
    Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G
    Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53 mutations in head and neck cancer.
    Nathan CA; Khandelwal AR; Wolf GT; Rodrigo JP; Mäkitie AA; Saba NF; Forastiere AA; Bradford CR; Ferlito A
    Mol Carcinog; 2022 Apr; 61(4):385-391. PubMed ID: 35218075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
    Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
    Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantified pathway mutations associate epithelial-mesenchymal transition and immune escape with poor prognosis and immunotherapy resistance of head and neck squamous cell carcinoma.
    Huang Y; Liu H; Liu B; Chen X; Li D; Xue J; Li N; Zhu L; Yang L; Xiao J; Liu C
    BMC Med Genomics; 2024 Feb; 17(1):49. PubMed ID: 38331768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of immune-related genes and immune cell infiltration analysis in the tumor microenvironment of head and neck squamous cell carcinoma.
    Wang Z; Yuan H; Huang J; Hu D; Qin X; Sun C; Chen G; Wang B
    Head Neck; 2021 Jan; 43(1):182-197. PubMed ID: 33009692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis.
    Chen X; Yan B; Lou H; Shen Z; Tong F; Zhai A; Wei L; Zhang F
    Mol Immunol; 2018 Apr; 96():28-36. PubMed ID: 29477933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-34a regulates epithelial-mesenchymal transition and cancer stem cell phenotype of head and neck squamous cell carcinoma in vitro.
    Sun Z; Hu W; Xu J; Kaufmann AM; Albers AE
    Int J Oncol; 2015 Oct; 47(4):1339-50. PubMed ID: 26323460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.
    Martin D; Abba MC; Molinolo AA; Vitale-Cross L; Wang Z; Zaida M; Delic NC; Samuels Y; Lyons JG; Gutkind JS
    Oncotarget; 2014 Oct; 5(19):8906-23. PubMed ID: 25275298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy.
    Tawk B; Wirkner U; Schwager C; Rein K; Zaoui K; Federspil PA; Adeberg S; Linge A; Ganswindt U; Hess J; Unger K; Tinhofer I; Budach V; Lohaus F; Krause M; Guberina M; Stuschke M; Balermpas P; Rödel C; Grosu AL; Schäfer H; Zips D; Combs SE; Pigorsch S; Zitzelsberger H; Baumeister P; Kirchner T; Bewerunge-Hudler M; Weichert W; Hess J; Herpel E; Belka C; Baumann M; Debus J; Abdollahi A;
    Int J Cancer; 2022 Feb; 150(4):603-616. PubMed ID: 34648658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas.
    Kolenda T; Guglas K; Kopczyńska M; Teresiak A; Bliźniak R; Mackiewicz A; Lamperska K; Mackiewicz J
    Cells; 2019 Apr; 8(4):. PubMed ID: 31010087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma.
    Citron F; Armenia J; Franchin G; Polesel J; Talamini R; D'Andrea S; Sulfaro S; Croce CM; Klement W; Otasek D; Pastrello C; Tokar T; Jurisica I; French D; Bomben R; Vaccher E; Serraino D; Belletti B; Vecchione A; Barzan L; Baldassarre G
    Clin Cancer Res; 2017 Jul; 23(14):3769-3780. PubMed ID: 28174235
    [No Abstract]   [Full Text] [Related]  

  • 34. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Chen TC; Wu CT; Wang CP; Lou PJ; Ko JY; Chang YL
    Oral Oncol; 2020 Dec; 111():104945. PubMed ID: 32769036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of epithelial-mesenchymal transition (EMT) and Gli1 expression in head and neck squamous cell carcinoma (HNSCC) spheroid cultures.
    Essid N; Chambard JC; Elgaaïed AB
    Bosn J Basic Med Sci; 2018 Nov; 18(4):336-346. PubMed ID: 30172250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Silencing the lncRNA NORAD inhibits EMT of head and neck squamous cell carcinoma stem cells via miR‑26a‑5p.
    Hu W; Zhao Y; Su L; Wu Z; Jiang W; Jiang X; Liu M
    Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34435652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
    Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
    J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decoding the associations between cell functional states in head and neck cancer based on single-cell transcriptome.
    Yuan H; Yan M; Liang X; Liu W; He S; Sun S; Zhang X; Lan Y
    Oral Oncol; 2022 Nov; 134():106110. PubMed ID: 36087501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
    Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.